Single nucleotide polymorphisms in apolipoprotein A-I (rs670) and B (rs693) associated with serum lipoproteins and endothelial activation in COVID-19 outpatients
DOI:
https://doi.org/10.1590/Keywords:
SARS-CoV-2, Single nucleotide polymorphism, Lipid metabolism, Vascular cell adhesion molecule-1Abstract
This cross-sectional study investigated the association of SNPs rs670 (C>T) and rs693 (G>A) with parameters of lipid metabolism and endothelial activation in 167 subjects, including 86 COVID-19 outpatients and 81 healthy subjects (control group) matched for sex and age. Serum levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), non-high-density lipoprotein cholesterol (non-HDL-c), triglycerides (TG), apolipoproteins (Apo A-I and B), and vascular cell adhesion molecule-1 (VCAM-1) were determined. The SNPs were genotyped by quantitative polymerase chain reaction (qPCR). A p -value<0.05 was assumed. COVID-19 outpatients showed increases in TC (187.0±48.3 vs . 160.8±32.0 mg/dL), LDL-c (110.3±41.5 vs . 98.8±28.2 mg/dL), non-HDL-c (138.3±45.8 vs . 115.6±31.6 mg/dL), TG (139.7±80.3 vs . 84.9±35.1 mg/dL), and Apo A-I (149.5±40.0 vs . 133.3±20.9 mg/dL), along with a high frequency of hypercholesterolemia and hypertriglyceridemia. VCAM-1 levels were double those of the control (682.7±231.8 vs. 299.3±102.9 ng/mL) and a strong predictor of COVID-19 (AUC=0.946). Moreover, VCAM-1 correlated with TC (r = -0.223) and HDL-c (r = -0.225). The decrease in TG and VCAM-1 is predicted by the dominance of the T allele (rs670) and its codominance with the A (rs693) allele in COVID-19 outpatients. COVID-19 has been shown to be associated with dyslipidemias and endothelial activation, and apolipoprotein polymorphisms may influence this.
Downloads
References
Abd-Elmawla MA, Fawzy MW, Rizk SM, Shaheen AA. Role of long non-coding RNAs expression (ANRIL, NOS3-AS, and APOA1-AS) in development of atherosclerosis in Egyptian systemic lupus erythematosus patients. Clin Rheumatol. 2018;37(12):3319–28.
Alkazmi L, Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Saad HM, et al. The potential role of scavenger receptor B type I (SR-BI) in SARS-CoV-2 infection. Immun Inflamm Dis. 2023;11(4).
Alves ES, Henriques AD, Tonet-Furioso AC, Paula RS, Gomes LO, Moraes CF, et al. The APOB rs693 polymorphism impacts the lipid profile of Brazilian older adults. Brazilian Journal of Medical and Biological Research. 2020;53(3):e9102.
Faguer S, Del Bello A, Danet C, Renaudineau Y, Izopet J, Kamar N. Apolipoprotein-A-I for severe COVID-19-induced hyperinflammatory states: A prospective case study. Front Pharmacol. 2022;13:936659.
Faludi AA, de Oliveira Izar MC, Saraiva JFK, Chacra APM, Bianco HT, Neto AA, et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017. Arq Bras Cardiol. 2017;109(2):1–76.
Fernández S, Moreno-Castaño AB, Palomo M, Martinez-Sanchez J, Torramadé-Moix S, Téllez A, et al. Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. Shock. 2022;57(1):95–105.
Fortaleza. Prefeitura de Fortaleza disponibiliza centros de testagem gratuita para COVID-19. Secretaria Municipal da Saúde. 2022.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
Guo Y, Li W, Qian M, Jiang T, Guo P, Du Q, et al. D-4F Ameliorates Contrast Media-Induced Oxidative Injuries in Endothelial Cells via the AMPK/PKC Pathway. Front Pharmacol. 2021;11.
Halley P, Kadakkuzha BM, Faghihi MA, Magistri M, Zeier Z, Khorkova O, et al. Regulation of the apolipoprotein gene cluster by a long noncoding RNA. Cell Rep. 2014;6(1):222–30.
Hsu MC, Lee KT, Hsiao WC, Wu CH, Sun HY, Lin IL, et al. The dyslipidemia-associated SNP on the APOA1/C3/A5 gene cluster predicts post-surgery poor outcome in Taiwanese breast cancer patients: a 10-year follow-up study. BMC Cancer. 2013;13.
Kalayci A, Gibson CM, Ridker PM, Wright SD, Kingwell BA, Korjian S, et al. ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future. Curr Atheroscler Rep. 2022;24(7):585–97.
Kimura T. [Non-coding Natural Antisense RNA: Mechanisms of action in the regulation of target gene expression and its clinical implications]. J Pharm Soc Japan. 2020;140(5):687–700.
Lee W, Ahn JH, Park HH, Kim HN, Kim H, Yoo Y, et al. COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm. Signal Transduction Targeted Ther. 2020;5(1):1–11.
Lin J. Low-density lipoprotein: Biochemical and metabolic characteristics and its pathogenic mechanism. Apolipoproteins, Triglycerides Cholesterol. 2020.
Liu N, Long H, Sun J, Li H, He Y, Wang Q, et al. New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression. J Med Virol. 2022;94(7):3112–20.
López-Reyes A, Martinez-Armenta C, Espinosa-Velázquez R, Vázquez-Cárdenas P, Cruz-Ramos M, Palacios-Gonzalez B, et al. NLRP3 Inflammasome: The Stormy Link Between Obesity and COVID-19. Front Immunol. 2020;11.
de Luis D, Izaola O, Primo D, Aller R. Role of rs670 variant of APOA1 gene on metabolic response after a high fat vs. a low fat hypocaloric diets in obese human subjects. J Diabetes Complications. 2019;33(3):249–54.
Maarfi F, Ahmad S, Alouffi S, Akasha R, Khan MS, Rafi Z, et al. Differential impact of glycation on apolipoprotein A-I of high-density lipoprotein: a review. Glycobiology. 2023;33(6).
Mackness M, Mackness B. Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene. 2015;567(1):12–21.
Magray JA, Pandith AA, Qasim I, Khateeb M, Hamid A, Koul A, et al. Significant implications of APOA1 gene sequence variations and its protein expression in bladder cancer. Biomedicines. 2021;9(8):938.
Makarova YA, Ryabkova VA, Salukhov VV, Sagun BV, Korovin AE, Churilov LP. Atherosclerosis, cardiovascular disorders and COVID-19: Comorbid Pathogenesis. Diagnostics (Basel). 2023;13(3).
Medina-Leyte DJ, Zepeda-García O, Domínguez-Pérez M, González-Garrido A, Villarreal-Molina T, Jacobo-Albavera L. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021;22(8):3850.
Miller YI, Choi SH, Wiesner P, Bae YS. The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDL. Br J Pharmacol. 2012;167(5):990–9.
Nasab EM, Aghajani H, Makoei RH, Athari SS. COVID-19’s immuno-pathology and cardiovascular diseases. Journal of investigative medicine. 2023;71(2):71–80.
NCBI. rs670 RefSNP Report - dbSNP - NCBI. National Library of Medicine. 2022.
Nguyen SD, Maaninka K, Lappalainen J, Nurmi K, Metso J, Öörni K, et al. Carboxyl-terminal cleavage of apolipoprotein A-I by human mast cell chymase impairs its anti-inflammatory properties. Arterioscler Thromb Vasc Biol. 2016;36(2):274–84.
Santos FAB, Lemes RB, Otto PA. HW_TEST, a program for comprehensive HARDY-WEINBERG equilibrium testing. Genet Mol Biol. 2020;43(2):e20190380.
Silva CA, Ferreira A, Freitas S, Martins BB, De E, Sá J, et al. Imunopatogênese no desenvolvimento da COVID-19. Rev Saúde Ciência Online. 2021;10(1):85–102.
Sultana A, Cochran BJ, Tabet F, Patel M, Torres LC, Barter PJ, et al. Inhibition of inflammatory signaling pathways in 3T3-L1 adipocytes by apolipoprotein A-I. FASEB J. 2016;30(6):2324–35.
Surma S, Banach M, Lewek J. COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection. Lipids Health Dis. 2021;20(1).
Swanson CR, Li K, Unger TL, Gallagher MD, Van Deerlin VM, Agarwal P, et al. Lower plasma apolipoprotein A1 levels are found in Parkinson’s disease and associate with apolipoprotein A1 genotype. Movement Disorders. 2015;30(6):805–12.
Tufa A, Gebremariam TH, Manyazewal T, Getinet T, Webb DL, Hellström PM, et al. Inflammatory mediators profile in patients hospitalized with COVID-19: A comparative study. Front Immunol. 2022;13:964179.
Wang J, Cai Y, Lu H, Zhang F, Zheng J. LncRNA APOA1-AS facilitates proliferation and migration and represses apoptosis of VSMCs through TAF15-mediated SMAD3 mRNA stabilization. Cell Cycle. 2021;20(17):1642–52.
Wu Y, Yu Y, Zhao T, Wang S, Fu Y, Qi Y, et al. Interactions of Environmental Factors and APOA1-APOC3-APOA4-APOA5 Gene Cluster Gene Polymorphisms with Metabolic Syndrome. PLoS One. 2016;11(1).
Yang HY, Jiang L. The involvement of long noncoding RNA APOA1-AS in the pathogenesis of preeclampsia. Hum Exp Toxicol. 2022;41.
Yao S, Luo N, Liu J, Zha H, Ai Y, Luo J, et al. Elevated Serum Levels of Progranulin and Soluble Vascular Cell Adhesion Molecule-1 in Patients with COVID-19. J Inflamm Res. 2021;14:4785.
Yin K, Chen WJ, Zhou ZG, Zhao GJ, Lv YC, Ouyang XP, et al. Apolipoprotein A-I inhibits CD40 proinflammatory signaling via ATP-binding cassette transporter A1-mediated modulation of lipid raft in macrophages. J Atheroscler Thromb. 2012;19(9):823–36.
Zhang M, Zhao GJ, Yin K, Xia XD, Gong D, Zhao ZW, et al. Apolipoprotein A-1 Binding Protein Inhibits Inflammatory Signaling Pathways by Binding to Apolipoprotein A-1 in THP-1 Macrophages. Circ J. 2018;82(5):1396–404.
Zhao Y, Han X, Li C, Liu Y, Cheng J, Adhikari BK, et al. COVID-19 and the cardiovascular system: a study of pathophysiology and interpopulation variability. Front Microbiol. 2023;14:1213111.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
